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Vitisthunbergii(VT)isawildgrapethathasbeenshowntoprovidevariouscardioprotectiveeﬀects.Thepresentstudywasdesigned
toexaminewhetheraVTextractcouldreduceserumlipidlevelsandpreventatherogenesisinahypercholesterolemicrabbitmodel.
Attheendofan8-weekstudy,ourresultsshowedthataVTextractsupplementmarkedlysuppressedtheserumlevelsofcholesterol
and low-density lipoprotein, reduced lipid accumulation in liver tissues, and limited aortic fatty streaks. Our ﬁndings suggest
that the VT extract activated AMPK (5 -adenosine monophosphate-activated protein kinase) with subsequent inhibition of the
activation of ACC (acetyl-CoA carboxylase). Our results suggest that this VT extract could be further developed as a potential
lipid-lowering agent and as a natural health food to prevent atherogenesis.
1.Introduction
The treatment and prevention of cardiovascular diseases,
particularly atherosclerosis, remains a critical research topic
for modern medicine. Atherosclerosis is a slow progressive
disease and is the most common cardiovascular disease
among Western societies, where it remains the leading cause
of both illness and death. Atherosclerosis may be initially
caused by damage to the inner layers (endothelium) of the
arteries from several risk factors, which include hyperc-
holesterolemia (or hyperlipidemia), hypertension, diabetes,
and cigarette smoking. Lipid-lowering agents, which include
statins and ﬁbrates, reduce the blood levels of fats such as
cholesterol and triglycerides and have become some of the
most common and eﬀective prescribed drugs for the treat-
ment of atherosclerosis. Nevertheless, the clinically adverse
side eﬀect of myotoxicity has been associated with the use of
lipid-lowering drugs, and this condition may eventually lead
to renal failure and death in the worst cases [1]. Accordingly,
developing new lipid-lowering agents or natural supple-
ments is an important issue that warrants further study.
AMPK (5 -adenosine monophosphate-activated protein
kinase) is a known physiological cellular senor for energy
homeostasis. This enzyme is composed of three parts (α,
β,a n dγ subunits) that bind together to make a functional
kinase. The energy-sensing capability of AMPK can be
attributed to its ability to detect and react to the changes
in the ratio of AMP/ATP molecules [2]. Under conditions
of fasting or an insuﬃcient energy supply, activated AMPK
regulates several intracellular metabolic systems to either
generate energy or reduce energy depletion. These metabolic
changes include increases in the cellular uptake of glucose
through inhibiting gluconeogenesis [3, 4] and the upreg-
ulation of the glucose transporter type 4 (GLUT4) [4, 5],
the acceleration of lipid catabolism via the suppression of
acetyl-CoA carboxylase (ACC) [6], inhibition of cholesterol
synthesis via depressed activity of HMG-CoA reductase
(HMGCR) [7], and decreased fatty acid de novo biosynthesis
via suppression of fatty acid synthase (FAS) [8]. Accordingly,
AMPK protein has the potential to be a therapeutic drug
target for the treatment of hyperlipidemia or atherosclerosis.
Vitis thunbergii (VT) is a wild grape that is native to
Taiwan and East Asia. It is widely used in medicinal wines
and beverages. Several natural components isolated from V.
thunbergii have been shown to provide various beneﬁcial
pharmacological eﬀects, including antiinﬂammation [9, 10],2 Evidence-Based Complementary and Alternative Medicine
antioxidation [11], antitumor [12], antiplatelet aggregation
[11], antimicrobial [13], and neuroprotective activities [14,
15].AlthoughsomeoftheisolatedcompoundsfromV. thun-
bergiihavecardioprotectiveeﬀects,theireﬀectsonlipidlevels
and atherosclerosis are unknown. Therefore, the purpose
of the present study was to evaluate whether V. thunbergii
could reduce serum lipid levels and prevent atherosclerosis
formation. This study also investigated whether the molec-
ular mechanisms underlying the lipid-lowering eﬀects of V.
thunbergii are associated with AMPK pathway activation.
2.MaterialsandMethods
2.1. Materials. V. thunbergii was kindly provided and plant
origin identiﬁed by Dr. Tzer-Kaun Hu (Department of
Agronomy, National Chung Hsing University, Taiwan).Anti-
phospho-ACC (#3661) and anti-phospho-AMPKα (#2531s)
were obtained from Cell signaling Technology, Inc. (Bev-
erly, MA, USA). The primary antibodies against β-actin
(#ab6276) and HMGCR (#07-457) were purchased from
Abcam (Cambridge, MA, USA) and Millipore/Upstate
(Bedford, MA, USA), respectively. Horseradish peroxidase-
labeled secondary antibodies against mouse IgG (#sc2005)
and rabbit IgG (#sc2004) were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). All other reagents
were purchased from Sigma-Aldrich (Louis, MO, USA).
2.2. Preparation of V. thunbergii Extract. V. thunbergii was
homogenized to a powder. Subsequently, the homogenized
material (about 1kg) was soaked in 10L of 50% ethanol
solution (extractive solvent) at 80◦Cf o r1 h r .T h es o l i d
residue of the extracted herbs was ﬁltered and discarded
through a Buchner funnel lined with Whatman ﬁlter paper.
The ﬁltrate was concentrated to a paste by distillation under
reduced pressure. The concentrated V. thunbergii extract was
further diluted with deionized water for all of the subsequent
experiments.
2.3. Experimental Model. Twenty-four male New Zealand
White rabbits (average of six-week-old) were purchased
from Lu-Hop ranch (Changhua, Taiwan). The animals were
housed in individual cages with free access to water and
maintained on a 12hr light/dark photocycle. All animal
care followed the institutional animal ethical guidelines of
China Medical University. After 1 week of adaptation, the
rabbits were randomly divided into four groups, which
were fed the following daily treatment diets for 8 weeks: a
regular diet (Control group; FwuSow Ind., Taiwan), 0.5%
(w/w) cholesterol diet alone (CHOL group), 0.5% (w/w)
cholesterol diet with 0.01% (w/w) lovastatin supplement
(LOVA group; YungShin Pharm. Ind., Taiwan), and 0.5%
(w/w) cholesterol diet with a 7% (w/w) V. thunbergii extract
supplement (VT group). The daily feeding amount for each
rabbit was 50g/kg body weight per day. At the beginning and
end of the 8-week study, the rabbits were anesthetized by
an intramuscular injection of Zoletil 50 (1mL/kg) (Virbac
Ltd., France), and blood samples were harvested. Finally,
the aortas (from aortic arch to the bifurcation of the iliac
arteries) and whole livers were collected from the rabbits
after they were sacriﬁced for further histopathological and
western blot analyses.
2.4. Blood Chemistry Analysis. T h ea n i m a l sw e r ef a s t e d
overnight before blood drawing. The blood was collected
from the marginal ear veins of rabbits into BD Vacutainer
EDTA Blood Collection Tubes. Plasma was separated by cen-
trifugationat3,000rpmat4◦Cfor10min.Measurementsfor
changesinbloodchemistryparametersincludedserumlevels
of low-density lipoprotein (LDL), cholesterol (Chol), triglyc-
erides (TG), glutamate oxaloacetate transaminase (GOT),
andglutamatepyruvatetransaminase(GPT)(ZhenXing Co.,
Ltd, Taiwan).
2.5. Cryosectioning of Liver Tissues. The rabbit liver tissues
were perfused with normal saline and ﬁxed in 10% (v/v)
formalin-neutralized solution (J.T. Baker, Inc., USA) for
24hr. Afterward, the tissues were embedded in Tissue-
Tek OCT Compound (#4583; Sakura Finetek Inc., USA).
Embedded tissues were cut into 10μm thick slices and
stained with Sudan IV and hematoxylin (Merck, USA).
Brieﬂy, the slices were washed with pure water for 1min to
remove the OCT compound, washed with 50% (v/v) ethanol
for 30sec, and then stained with 2% (w/v) Sudan IV for 1hr.
After further washing with 50% (v/v) ethanol and pure water
for 2min, the slices were counterstained with hematoxylin.
Photographs were acquired using a microscope equipped
with a 10-fold magniﬁcation objective and quantiﬁed on an
Alpha Imager 2200 documentation system (Alpha Innotech,
USA). The manifestation of fatty liver progression was
presented as the percentage of the area of oil droplets to the
total liver tissues (cells).
2.6. Aortic Fatty Streak Staining. The aortas were opened
longitudinallytoexposetheintimalsurfaceandrinsedgently
with normal saline. Aortas were incubated in 2% (w/v)
Sudan IV, rinsed with several concentrations (100%, 90%,
80%, 70%, and 60%) of ethanol for 1min, and then rinsed
with pure water. The photographs were acquired using a dig-
ital camera (Nikon D80, Japan) and quantiﬁed on an Alpha
Imager 2200 documentation system (Alpha Innotech, USA).
The progression of the fatty streak lesions was presented as
the percentage of the stained area to the total area.
2.7. Western Blot. Proteins extracted from the frozen liver
tissues were subjected to SDS-PAGE under reducing condi-
tions on 10% acrylamide gels and transferred to polyvinyli-
dene ﬂuoride (PVDF) membranes by electroblotting. After
blockade of nonspeciﬁc binding sites, membranes were incu-
bated with primary antibodies (1:1,000 dilution), followed
by horseradish peroxidase-conjugated secondary antibod-
ies (1:2,000 dilution). Protein expression was visualized
using SuperSignal West Pico Chemiluminescent Substrate
(Thermo Scientiﬁc, USA), and the luminescence signal was
acquired and analyzed with a Fujiﬁlm LAS-4000 system
(Japan). The amounts of p-AMPKα, p-ACC, and HMGCREvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Blood chemistry parameters were measured in the hypercholesterolemic rabbit model after the 8-week study. Control group:
regular diet; CHOL group: 0.5% (w/w) cholesterol diet alone; LOVA group: 0.5% (w/w) cholesterol diet with 0.01% (w/w) lovastatin; VT
group: 0.5% (w/w) cholesterol diet with 7% (w/w) V. thunbergii extract. ∗ and † indicate a P<0.05 as compared with the control group and
CHOL group, respectively.
were expressed relative to the amount of β-actin (loading
control).
2.8. Statistical Analysis. A l lv a l u e sa r ee x p r e s s e da sm e a n±
standard deviation (SD). Data were compared with a one-
way analysis of variance (ANOVA) to evaluate diﬀerences
among multiple groups. A value of P<0.05 was considered
statistically signiﬁcant.
3. Results
3.1. Regulatory Eﬀect of VT Extract on Serum Lipids. The
blood chemistry parameters were examined to evaluate
whether the VT extract could reduce serum lipids (Figure 1).
Our data revealed that the plasma level of cholesterol, LDL,
triglycerides, HDL, GOT, and GPT did not signiﬁcantly
vary among the diﬀerent groups prior to study (data not
shown). At the end of the 8-week study, our results showed
that a 0.5% (w/w) cholesterol diet markedly stimulated
plasma levels of cholesterol, LDL, and HDL (Figures 1(a),
1(b),a n d1(d)) and slightly increased triglyceride levels
without statistical signiﬁcance (Figure 1(c)). Under the same
conditions, a 7% (w/w) VT extract signiﬁcantly reversed a
0.5% (w/w) cholesterol diet-induced accumulation of serum
lipids, which was similar to the eﬀect in the LOVA group
(Figures 1(a) and 1(b)). Besides, the serum LDL/HDL ratio4 Evidence-Based Complementary and Alternative Medicine
(a) (b)
(c) (d)
Figure 2: Photographs of liver appearance in the hypercholesterolemic rabbit model after the 8-week study. (a) Control group; (b) CHOL
group; (c) LOVA group; (d) VT group.
was increased by 0.5% (w/w) cholesterol diet (ratio = 1.97)
as compared with control group (ratio = 0.36), which can
be reversed by 7% (v/v) VT supplement (ratio = 1.26).
Furthermore, the experimental data also demonstrated that
a 7% (w/w) VT extract supplement did not cause obvious
liverdamageortoxicity,whichwasdeterminedbyexamining
plasmalevelsofGOTandGPTattheendofthe8-weekstudy
(Figures 1(e) and 1(f)).
3.2. Regulatory Eﬀe c to fV TE x t r a c to nF a t t yL i v e rD i s e a s ea n d
Lipid Accumulation. After the 8-week study, a histopatho-
logical analysis of liver cryosections was performed in order
to determine whether the VT extract could prevent the
formation of fatty liver (Figure 2) and lipid accumulation
within liver tissues (Figure 3). Our data demonstrated that
a 0.5% (w/w) cholesterol diet could induce phenomena
resembling fatty liver (Figure 2(b)) and a 7% (w/w) VT
extract reduced the severity of cholesterol diet-induced fatty
liver (Figure 2(d)). Similarly, a 0.5% (w/w) cholesterol diet
also increased lipid (or oil droplets) accumulation within
the liver tissues (Figures 3(b) and 3(e)), and this eﬀect was
markedly reversed by a 7% (w/w) VT extract supplement
(Figures 3(d) and 3(e)), which was similar to the results of
the LOVA group (Figures 3(c) and 3(e)).
3.3. Regulatory Eﬀect of VT Extract on Atherosclerosis Forma-
tion. Sudan IV staining of the fatty streak lesions within the
aorta was used to estimate whether the VT extract could
reduce the formation of atherosclerosis plaques after the 8-
week study (Figure 4). The present study showed that a 0.5%
(w/w)cholesteroldietcoulddramaticallyincreaseaorticfatty
streak lesions as compared with the control group (Figures
4(a), 4(b),a n d4(e)). In addition, a 7% (w/w) VT extract
markedly reduced the intensity of fatty streaks on the aorta
intima as compared with the CHOL group (Figures 4(b),
4(d),and4(e)),whichwasthesameresultastheLOVAgroup
(Figures 4(b), 4(c),a n d4(e)).
3.4. Regulatory Eﬀect of VT Extract on Lipid Metabolism-
Associated Proteins. Lipid metabolism-associated proteins
such as AMPK, ACC, and HMGCR were examined to de-
termine the molecular mechanisms underlying these VT
extract-induced lipid-lowering eﬀects (Figure 5(a)). Experi-
mentaldatarevealedthatthe8-weektreatmentwiththe0.5%
(w/w) cholesterol diet signiﬁcantly decreased the protein
expression of phospho-AMPK (Figure 5(b)), phospho-ACC
(Figure 5(c)), and HMGCR (Figure 5(d)). The addition of a
7% (w/w) VT extract clearly returned the expression of theseEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: Histopathochemical examination of liver tissues in the hypercholesterolemic rabbit model after the 8-week study. (a) Control
group; (b) CHOL group; (c) LOVA group; (d) VT group; (e) relative lipid accumulation within liver tissues among diﬀerent groups. ∗ and †
indicate a P<0.05 as compared with the control group and CHOL group, respectively.
proteins to near basal levels as compared with the CHOL
group, which was the same result as the LOVA group.
4. Discussion
Cardiovascular diseases such as coronary heart disease and
myocardialinfarctionarecomplicationsofatherosclerosis.In
addition, abnormalities in lipid metabolism and coagulation
are major contributors to the pathology of atherosclerosis. V.
thunbergii has been demonstrated to provide many cardiac
beneﬁts that may be modulated through some of its identi-
ﬁed components, which include the following compounds:
β-sitosterol, β-sitosterol-3-O-β-D-glucoside, ampelopsin C,
betulinic acid, botulin, caﬀeic acid, friedelin, heyneanol A,
l-dotriacontanol, lupeol, luteolin-7-O-glucoside, miyabenol
A, narcissin, oligostilbenes, piceatannol, quercetin-3-O-gal-
actoside, quercitrin, rutin, stigmasterol, triacontanoic acid,
vanillicacid,viniferin,viniferal,vitisinA,vitisinC,andvitis-
inols A-D [11–13, 16, 17]. Of these components, ampelopsin
C, miyabenol A, viniferin, viniferal, vitisin A, vitisin C, and
vitisinols A-D belong to the class of resveratrol derivatives.
Resveratrol is a polyphenolic antioxidant that is found in
grape skin and is strongly related to the cardioprotective
eﬀect of red wine [18], which is a potent atheroprotective
compound [19, 20]. Growing evidences suggest that resver-
atrol protects the cardiovascular system in numerous ways,
including antiapoptotic [21, 22], antiplatelet [11, 23, 24],
antioxidative [25–27], and antiinﬂammatory eﬀects [28–30],
as well as regulating lipid metabolism [20, 31].
The regulation of lipid metabolism by resveratrol is re-
lated to the modulation of lipid turnover, inhibition of ei-
cosanoidproduction,andpreventionoflow-densitylipopro-
tein oxidation [31]. Several in vivo studies have revealed
that resveratrol can reduce plasma levels of LDL, cholesterol,6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Histopathochemical examination of aortic fatty streak lesions in the hypercholesterolemic rabbit model after the 8-week study.
(a) Control group; (b) CHOL group; (c) LOVA group; (d) VT group; (e) relative area of fatty streak lesion on aortic intima among diﬀerent
groups. ∗ and † indicate a P<0.05 as compared with the control group and CHOL group, respectively.
and triglycerides in high cholesterol diet-induced hyperc-
holesterolemia in rodent models [32–34]. Similarly, long-
term resveratrol administration can also decrease plasma
levels of triglycerides, total cholesterol, and free fatty acids
and hepatic total lipids in obese Zucker rats [35]. Ahn
et al. [36] demonstrated that a supplementary diet with
resveratrol can reduce atherosclerotic lesions and found that
it decreased the levels of total hepatic lipids and triglycerides
as well as their accumulation. In addition, mRNA expression
and enzymatic activity of hepatic HMG-CoA reductase can
also be downregulated by treatment with resveratrol, which
may result in decreased cholesterol synthesis [37, 38]. In
vitro studies have also shown promising beneﬁcial eﬀects
of resveratrol on lipid metabolism. In isolated normal rat
hepatocytes, resveratrol reduced the synthesis of fatty acids
and triglycerides, which suggests a possible mechanism
underlying resveratrol’s eﬀects in reducing the levels of tri-
glycerides and other lipoprotein in the circulation [39].
Goldberg et al. [40] indicated that resveratrol eﬀectively
reduced LDL production and modulated hepatic lipid meta-
bolism via decreasing secretion of triglycerides and choles-
terol esters in HepG2 cells. Our results indicated that the
VT extract reduced the plasma levels of cholesterol and
LDL (Figure 1), decreased lipid accumulation in liver tissues
(Figures 2 and 3), and diminished aortic fatty streak lesions
(Figure 4). These lipid-lowering eﬀects of the VT extract
may be partially explained by the activities of the resveratrol
derivatives mentioned previously.
Epidemiological studies have consistently shown that
serum HDL concentration is inversely correlated with the
incidence of cardiovascular disease. However, it appears
that the relationship between HDL and CVD risk is moreEvidence-Based Complementary and Alternative Medicine 7
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Figure 5: Protein expression of lipid metabolism associated molecules in the hypercholesterolemic rabbit model after the 8-week study. ∗
and † indicate a P<0.05 as compared with the control group and CHOL group, respectively.
complex and not just merely related to the serum HDL
levels. Barter et al. [41] noted that torcetrapib can markedly
increase the serum HDL, but the results of clinical trial
showed to increase the risk of deaths and cardiac events in
patients receiving torcetrapib. Several studies also showed
that serum HDL levels are not always consistent with the
incidence of CVD [42, 43]. In the present study, the results
showed that high-cholesterol diet can markedly induce the
serum levels of both LDL and HDL (Figures 1(b) and 1(d)),
whose eﬀects have be reported by others [44, 45]. Thereby,
evaluating CVD risk on the basis of serum HDL concentra-
tionalonemaybemisleading,andtheserumLDL/HDLratio
should also be evaluated together for CVD risk assessment.
Ourdatashowedthatthehigh-cholesteroldietleadstoaﬁve-
fold increase in the serum LDL/HDL ratio as compared with
controlgroupandVTsupplementcanreversethisparameter
to support its lipid-lowering eﬀect in the present study.
AMPK plays a critical role in the modulation of lipid
metabolism by inhibiting the activation of ACC and
HMGCR, which results in the acceleration of fatty acid oxi-
dation and the suppression of cholesterol biosynthesis. Nu-
merous studies have indicated that the stimulating activity of
the AMPK pathway can eﬀectively regulate lipid metabolism.
Adiponectin is an adipocyte-derived adipokines and can
protect against alcoholic fatty liver disease via the activation
of the SIRT1- (sirtuin 1-) AMPK pathway [46]. Kusakabe
et al. reported that leptin decreased liver and skeletal mus-
cle triacylglycerol content, which was accompanied by an
increase of AMPK activity in skeletal muscle [47]. Lin et al.
found that theaﬂavins signiﬁcantly reduced lipid accumula-
tion, suppressed fatty acid synthesis, and stimulated fatty
acid oxidation via stimulating AMPK and then inhibiting
ACC activity [48]. Luteolin is another component identiﬁed
from V. thunbergii that has been shown to reduce lipid
accumulation in HepG2 cells. This eﬀect may be partially
mediated by that activation of the AMPK signaling pathway,
which upregulates carnitine palmitoyl transferase 1 (CPT-1)
and downregulates sterol regulatory element binding protein
1c (SREBP-1c) and FAS gene expression [49]. Metformin
is an oral antidiabetic drug that has been demonstrated to
lower the hepatic lipid content by activating AMPK, which
may mediate the beneﬁcial eﬀects of this drug in hypergly-
cemia and insulin resistance [50, 51]. In addition, a number
of studies have also demonstrated that resveratrol treatment
can stimulate AMPK activity by regulating lipid metabolism
[35, 52–54]. In the present study, the data showed that a VT
extract could stimulate phosphorylation of AMPK and ACC
(Figure 5). However, this eﬀect may be partially mediated by
some of the bioactive components of the VT extract, such as
luteolinandtheresveratrolderivativesmentionedpreviously.
On the other hand, previous studies have demonstrat-
ed that activated AMPK will phosphorylate and then inacti-
vate HMGCR [7]. Nevertheless, the total protein expression
of HMGCR was upregulated by supplementation with the
VT extract in the present study. HMGCR is regulated via a
negative feedback mechanism that is mediated by sterols and8 Evidence-Based Complementary and Alternative Medicine
nonsterol metabolites derived from mevalonate. Moreover,
this enzyme is suppressed by cholesterol in mammalian cells
[55–57]. Therefore, the upregulation of HMGCR protein
after an 8-week dietary supplement with the VT extract may
have been triggered by the low levels of serum cholesterol
(Figure 1).
5. Conclusions
Our experimental study revealed that a VT extract supple-
ment can reduce serum LDL/HDL ratio as well as plasma
levels of cholesterol and LDL, decrease lipid accumulation
in tissues, and diminish aortic fatty streak lesions. Moreover,
the lipid-lowering eﬀects of the VT extract may have been
partially mediated by the activation of AMPK, which was
followed by the inhibition of the activation of ACC. These
results suggest that V. thunbergii may have the potential to be
developed as a lipid-lowering therapeutic agent or medicinal
healthfoodforthepreventionortreatmentofcardiovascular
diseases such as atherosclerosis.
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